Novavax (NVAX) COVID-19 Vaccine Approval Delayed in India - Report

November 29, 2021 7:32 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Novavax (NASDAQ: NVAX) shares are on watch following reports from Republicworld that the company's application to the Drugs Controller General of India seeking approval of its COVID-19 vaccine 'Covovax' is delayed as an expert panel asks for more data.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk